Antonietta P. Falcone
Brindisi, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).
Journal: Hematological oncology
Published: November 13, 2025
Single versus double autologous stem cell transplantation and lenalidomide maintenance versus no maintenance therapy in newly-diagnosed patients with multiple myeloma: a real-life, vintage snapshot after twenty-three years from the Rete Ematologica Pugliese.
Journal: Annals of hematology
Published: July 19, 2025
An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapies.
Journal: Annals of hematology
Published: April 18, 2025
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial.
Journal: Haematologica
Published: February 11, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.
Journal: European journal of haematology
Published: January 31, 2025
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial.
Journal: The Lancet. Haematology
Published: January 30, 2025
Clinicians' Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy.
Journal: Clinical lymphoma, myeloma & leukemia
Published: January 20, 2025
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).
Journal: Cancer
Published: October 24, 2024
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study.
Journal: HemaSphere
Published: July 31, 2024
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.
Journal: European journal of haematology
Published: July 23, 2024
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
Journal: Hematological oncology
Published: April 29, 2022
Last Updated: 09/26/2026